These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29862486)

  • 21. Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure.
    Vizzardi E; D'Aloia A; Giubbini R; Bordonali T; Bugatti S; Pezzali N; Romeo A; Dei Cas A; Metra M; Dei Cas L
    Am J Cardiol; 2010 Nov; 106(9):1292-6. PubMed ID: 21029826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction.
    Serenelli M; Jackson A; Dewan P; Jhund PS; Petrie MC; Rossignol P; Campo G; Pitt B; Zannad F; Ferreira JP; McMurray JJV
    JACC Heart Fail; 2020 Mar; 8(3):188-198. PubMed ID: 31926854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF).
    Edelmann F; Schmidt AG; Gelbrich G; Binder L; Herrmann-Lingen C; Halle M; Hasenfuss G; Wachter R; Pieske B
    Eur J Heart Fail; 2010 Aug; 12(8):874-82. PubMed ID: 20538867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of the Mineralocorticoid Receptor and Mineralocorticoid Receptor-Directed Therapies in Heart Failure.
    Young MJ; Kanki M; Karthigan N; Konstandopoulos P
    Endocrinology; 2021 Nov; 162(11):. PubMed ID: 34050730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
    Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA;
    Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.
    Vardeny O; Claggett B; Vaduganathan M; Beldhuis I; Rouleau J; O'Meara E; Anand IS; Shah SJ; Sweitzer NK; Fang JC; Desai AS; Lewis EF; Pitt B; Pfeffer MA; Solomon SD;
    JACC Heart Fail; 2019 Dec; 7(12):1022-1028. PubMed ID: 31779923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myocardial Effects of Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction.
    McDiarmid AK; Swoboda PP; Erhayiem B; Bounford KA; Bijsterveld P; Tyndall K; Fent GJ; Garg P; Dobson LE; Musa TA; Foley JRJ; Witte KK; Kearney MT; Greenwood JP; Plein S
    J Am Heart Assoc; 2020 Jan; 9(1):e011521. PubMed ID: 31852424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction.
    Kurrelmeyer KM; Ashton Y; Xu J; Nagueh SF; Torre-Amione G; Deswal A
    J Card Fail; 2014 Aug; 20(8):560-8. PubMed ID: 24905296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different implication of elevated B-type natriuretic peptide level in patients with heart failure with preserved ejection fraction and in those with reduced ejection fraction.
    Ishigaki T; Yoshida T; Izumi H; Fujisawa Y; Shimizu S; Masuda K; Asanuma T; Okabe H; Nakatani S
    Echocardiography; 2015 Apr; 32(4):623-9. PubMed ID: 25115860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCAT.
    Ferreira JP; Rossello X; Eschalier R; McMurray JJV; Pocock S; Girerd N; Rossignol P; Pitt B; Zannad F
    JACC Heart Fail; 2019 Dec; 7(12):1012-1021. PubMed ID: 31779922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of spironolactone on ventricular-arterial coupling in patients with chronic systolic heart failure and mild symptoms.
    Vizzardi E; Sciatti E; Bonadei I; D'Aloia A; Tartière-Kesri L; Tartière JM; Cohen-Solal A; Metra M
    Clin Res Cardiol; 2015 Dec; 104(12):1078-87. PubMed ID: 26058790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Spironolactone on Exercise Tolerance and Arterial Function in Older Adults with Heart Failure with Preserved Ejection Fraction.
    Upadhya B; Hundley WG; Brubaker PH; Morgan TM; Stewart KP; Kitzman DW
    J Am Geriatr Soc; 2017 Nov; 65(11):2374-2382. PubMed ID: 28542926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
    Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC
    J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure.
    Kasama S; Toyama T; Sumino H; Kumakura H; Takayama Y; Minami K; Ichikawa S; Matsumoto N; Sato Y; Kurabayashi M
    Int J Cardiol; 2013 Jul; 167(1):244-9. PubMed ID: 22245478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort.
    Kobayashi M; Ferreira JP; Duarte K; Bresso E; Huttin O; Bozec E; Brunner La Rocca HP; Delles C; Clark AL; Edelmann F; González A; Heymans S; Pellicori P; Petutschnigg J; Verdonschot JAJ; Rossignol P; Cleland JGF; Zannad F; Girerd N;
    Eur J Heart Fail; 2024 May; 26(5):1231-1241. PubMed ID: 38528728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF.
    Ferreira JP; Rossignol P; Machu JL; Sharma A; Girerd N; Anker SD; Cleland JG; Dickstein K; Filippatos G; Hillege HL; Lang CC; Ter Maaten JM; Metra M; Ng L; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zwinderman AH; Voors A; Zannad F
    Eur J Heart Fail; 2017 Oct; 19(10):1284-1293. PubMed ID: 28580625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy and safety of long-term application of spironolactone in patients with moderate and severe chronic heart failure receiving optimal therapy].
    Skvortsov AA; Mareev VY; Chelmakina SM; Baklanova NA; Belenkov IuN
    Kardiologiia; 2007; 47(10):12-23. PubMed ID: 18260939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Left ventricular global longitudinal strain is associated with exercise capacity in failing hearts with preserved and reduced ejection fraction.
    Hasselberg NE; Haugaa KH; Sarvari SI; Gullestad L; Andreassen AK; Smiseth OA; Edvardsen T
    Eur Heart J Cardiovasc Imaging; 2015 Feb; 16(2):217-24. PubMed ID: 25552469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.